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implicated in the process of abrupt vessel dosure and in late 
restenosis after angioplasty (4-7). Vascular injury initiates 
platelet adhesion and subsequent aggregation as platelets 
become activated by collagen, serotonin, epinephrine, throm- 
bin and other agonists (8-10). These local agonists activate 
platelets and result in a conformational change in the glyco- 
protein IIbAIIa (GP IMIIa) receptors on the platelet surface, 
which then bind circulating fibrinogen, von Willebrand factor 
and other adhesive proteins. This sequence leads to platelet 
aggregation and subsequent thrombosis (8-11). 
Recent data (12-14) have suggested that agents that block 
the platelet GP IIb/IIIa receptor may reduce the. incidence of 
both early ischemic complications after angioplasty and ooro- 
nary restenosis. In a large ran&m&d trial of patients under- 
going high risk angioplasty, the combined end point of death, 
myocardial infarction or urgent revascularization at 30 days 
U735-1097/9E&15.00 
tm5-1097(95-5 
JAE Vd. 27, No. 3 KmEhKEsElAL 537 
Mazda I. 1!B6536-42 TIROFUIAN THERAPY IN HIGH RISK ANGIWIASW 
was reduced 35% by treatment with a chimeric antii to the 
G? IIb/IIIa integrin as compared with treatment with placebo 
(15). ‘lhis bene6cial et&t was achieved at the expense of a 
15% incidence of hemonhage requiring blood tramfusion. 
Tii is a new mmpeptide tymsine derivative antagor&t of 
the RGD binding site on the platelet GP IIb/IIIa receptor that 
has demousttated antikomhotk etlicaq in auimal models of 
thrombosis (16). Preliminary studies with this agent in humans 
(17,18) have demonstrated a dose-related inhibii of platelet 
fumxionandprokmgationofbieedmgtimeinnormalvohm- 
teea Accordingly, the purpose of this mr&m&xk dmrble- 
blimt pkiahxontroUed dose-ran& shdy was 1) to examine 
thesafetyandtoIerabilityofti&ibangiveninconjun&onwith 
hepin and aspirin in higb risk patients undergoing angio- 
plasty, 2) to study the pharmacodynamics and @rmaa&met- 
icSoftiro6baninconjmxtionwithheparinandaspirin,and3) 
to evahtate the incidence of adverse cardiac outcomes (urgent 
repeat revasdarization, nonhtai myocardial infarction and 
deatb) witb tiro6ban versus placebo during the subsequent 
hospital stay. 
Tbk study was designed spedbUy to develop a rational 
tiroliban dosing regimen during angioplasty and to prcwide 
preliminaryevidenceofthesafetyandefficacyofuseofthis 
regimen. 
M&hOdS 
Wpeti-h=J eard&ntui&a.Thistrialwasa 
m&center, randomized double blind, placebocontrolled 
k-ranging study amducfed in nine clinical centers (see 
Appendix). Patients eligiie for study enrollment included men 
and women 118 and ~75 years of age who were scheduled to 
undergo coronary ang@lasty for treatment of 1) rest angina 
pectoris [onset witbin 5 days of angiopMy], 2) recurrent 
angina [r24 h and <5 days after myocardial infarction], or 3) 
complex coronary lesion morphology asccciated with a mod- 
erate to high risk of praxduml failure as descrii by the 
American Heart Association/American College of Cardiology 
(AHA/ACC) Task Force on Coronary Angioplasty (19) and 
mod&d by Ellis et al. (20). This category included patients 
with AHA/ACC type B or type C target lesion mo@ology. 
!Specik exclusion criteria included women of childbearing 
potential, and patients who had thrombolytic theran within 
24 b of angioplasty, severe ditIuse multivessel coronary athero- 
sclerosis, unamtroUed cardiac adythmih past or present 
Needing disorder or increased bleeding risk, history of stroke 
or other intracranial pathology, severe congestive heart failure 
or hemodynamic instability and allergy or intolerance to 
aspirin or heparin. 
‘%is study was approved by the institutional review board of 
each institution and informed consent was obtained from each 
patient. Alter coronary art*, patients were observed 
during the remainder of their hospital stzy for chnical outcome 
and bleeding complications. 
AnglopIasty pmcedore. All patients received aspirin 
(325 mg orally) before angioplasty, and intravenous heparin 
(initial bolus 1OJlOO U; subsequent bohrses of 2JKltl U) was 
administered during the procedure to achieve a target in- 
laboratory activated dotting time of 300 to 350 s A comirmous 
intravenous infu&m of heparin (1,008 U/h) was initiated after 
at@op&ytoachieveatargetactivatedpartialthromboplastin 
time of 60 to 80 s. Weight adjustment of heparin therapy for 
patients weighing <75 kg was pre+c&d in the protocol. In 
these patients the initial bohts of heparin was limited to 150 
U/kg body weight and the infusion to 15 U/kg per h. Either 
activestudydrugorplacebowasrtdmi&eredimmediately 
afterthecoronaryguidewirecrossedthestenoskAcontinu- 
ousinfu&mofstudydrugorplaceboandheparinwasthen 
admhktered for 16 to 24 h after the ar@op&y procedure, at 
which time these agents were discontinued simultaneously. 
Vascular access sheaths were removed 4 h after discontinua- 
tionofintravenousheparinandstudydrug 
Treatment aIbwhL Tbree dose regimens of timtIban 
were studied in three sequential panels. Patients within each 
panel were randomiaed to receive either tiroliban or placebo in 
a 3:l randomization design. Patients received one of three 
gratiuated regimens of tirofiban intravenously with a bohrs 
dose of 5, 10 and 10 &g and continuous infusion doses of 
0.05,O.lO and 0.15 & per min in dose panels I, II and III, 
mpectively. Data from patients receiving placeho (heparin 
only) in each panel were pooled across panels for comparison. 
Iabomtoty stedks. The pbarmaoodynamic effect of tirofi . 
ban on bleeding time and ex vivo platelet aggregation in 
respom to 5 -l/liter adenosine diphosphate (ADP) were 
evaluated before and after study drug administration. Blood 
was collected in 3.8% sodium citrate tubes, and platelet 
aggRgation was measured hy tbe turbidimetric method using 
5 ml/liter ADP. Platelet aggregation was quantified as the 
maximalchangeinlighttram&&noccurrmgwithin5mincf 
addition of agonist. Posttnxtment platelet aggregation was 
expressed as a percent of each patient’s pretreatment level of 
aggregation. Data were reported as percent inhibition of 
aggregation. Bleeding times were determined by the template 
technique of Ivy et al. (21) as performed by an automated 
&+&-Jl-ma&g insmment (!&plate II, C&anon Teknika 
Corporation). Bkeding times ~30 min were truncated and the 
measurement was reported as 30 min. Bleeding time data are 
reported as fold-extension (bleeding time at 2 h/bleeding time 
at baseline). 
cliaial and pa&s. AU patients were observed for adverse 
chical outcome of the ar@opMy procedure, including death, 
need for urgent repeat revascularization or nonfata! myocar- 
dial infarction within 24 h of the procedure and during the 
subsequent hospital stay. Angioplasty success was defined as 
final v&ally assessed iameter percent stenosis <50% in the 
absence of any of these adverse outcomes. Major bleeding 
complications were defined as 1) 25.0 g/d) decrease in hemo 
glohin, 2) need for packed red bloud cell transfusion. 3) 
corrective vascular surgery, 4) intracraniai or retroperitoneal 
hemorrbage, or 5) hemorrhage requiring discontinuation of 
thcstudydruginanattempttoachievebemostasis 
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Table 1. Patient Characteristics 
-- 
Age W 
Weigh1 (49 
Gender 
Male 
Femak 
Resentalion 
UNIabk angioa 
Poxmqwardial infarction angina 
Complex kxioo 
Complex lesion + unstable angina 
Complex lesion + fmstmyocardial infarction 
History 
Myocardid infarction 
Prior curunary angiopia5Iy 
Prior coronary bypas surgery 
Smotcr 
Diabeles 
tiyperlension 
Hypercholesterolemia 
Peripheral wcular disease 
Extent of coronary artery disease 
sigk vesel 
Doubk vessel 
Triple veal 
Left main 
Graft stew&s 
Tirotiban + Heparin 
(n = 73) 
58.2 2 II.0 
85.2 r 17.0 
61(w) 
IL(M) 
5 (7) 
0 (0) 
33 (45) 
25 WI 
lO(14) 
53 i-3 
1u (2.5; 
I1 (15) 
27 (37) 
18 (251 
37 (51; 
41(56) 
7(1’) 
3: (44) 
23 (32) 
17 (2.3 
l(1) 
6 (8) 
Plac-ebo + Heparin 
(n = 20) 
59.6 ? 10.0 
87.9 f m.0 
I5 (75) 
5 PJ 
0 (0) 
0 (0) 
12 WV 
6W 
2 (10) 
II (55) 
3(15) 
3(15) 
II (55) 
4(m) 
12 w 
10 (W 
3(15) 
9 (45) 
8 W 
3(15) 
10) 
10) 
Data are presented ax mean value + SD or number (%) of patients. 
Statistiepl analysis. Descriptive statistics for population 
demographics include frequency counts and means and stan- 
dard deviations for continuous variables, with data from the 
patients receiving tirofiban and those receiving placebo each 
pooled across all three panels. Inhibition of ADP-mediated 
platelet aggregation and bleeding times are described (fcr each 
panel) as median, mean, lOth, 25th, 75th and 90th percentiles. 
Due to the nonnormality of the platelet inhibition data result- 
ing from the almost complete response (100% inhibition of 
ADP-mediated aggregation) of subjects receiving higher doses 
of tirofiban, an ad hoc Jonckheere-Terpstra test for increasing 
trend with dose was conducted. A Wilcoxon rank sum test was 
used to test the difference from placebo at each dosage level of 
tirofiban, for both inhibition of platelet aggregation and bleed- 
ing time extension. All p values provided potentially overstate 
the level of significance because they were not adjusted for 
multiple comparisons, given the absence of prespecified hy- 
pothesized comparisons in the protocol (the focus of the trial 
was on estimation rather than formal hypothesis testing). 
Because of the very small sample size (about 20 patients/ 
group), the trial had little power to detect a clinically mean- 
ingful reduction (33% reduction) in clinical events between the 
tiroliban and placebo groups. For example, if the majc,r 
adverse clinical event rate was 15% in the heparin group, with 
20 patientslgroup there is only 5% power to detect a statisti- 
cally sign&ant (p = 0.05) reduction in event rate to 10%. 
Therefore, no formal comparative statistics were performed. 
Results 
Study patients. Baseline patient demographics are summa- 
rized in Table 1 for the 73 patients receiving tirofiban and the 
20 patients who received placebo. Approximately 48% of 
patients were enrolled on the basis of complex coronary lesion 
morphology alone. 
Pharmeeodpami responses. The median percent inhiii- 
tion of ex vivo platelet aggregation in response to 5 WI/liter 
ADP as well as median bleeding times at 2 h of study drug 
infusion are shown in Table 2. The inhibition of platelet 
aggregation was rapid in onset with 93% to %% inhibition 
observed 5 min after administration of the tirofiban bolus in 
panels I1 and 111, respectively. Inhibition of platelet aggrega- 
tion was sustained during continuous intravenous infusion of 
tirofiban and was most marked at the higher dose panels II and 
111 (Fig. IA). The increase in inhibition with increasing dose 
levels of tirofiban at 5 min, 2 h and end of the infusion was 
highly significant (p < 0.001 by the Jonckheere test). No 
inhibition of platelet aggregatior was noted in patients receiv- 
ing heparin only (placebo); the difference between tirofiban 
doses and placebo at all time points was also highly sign&ant 
(p < 0.001). Although no effect of heparin on ex vivo platelet 
aggregation was seen, there was a 2.1-fold rise (to 11 min) in 
the median bleeding time observed at 2 h of treatment in the 
placebo group. The median increase in panel I was 2.9-fold (to 
19.5 min) (p = 0.118 [NS] vs. placebo). Median bleeding times 
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Table 2. Pharmacodlnamics of Tiifiban on Ex Vivo Platelet Aggregation and Bleeding Tiies in 
Patients Treated Wh rleparin and Aspirin 
-- 
i&St Panel I (II = 21) Do% Panel II (n = xl) the Panel 111 (n = 22) 
The 46 hhib BT mu Ihbib B-r w9 % Inbii RI- w’) 
Before drug 0% 55 0% 5 0% 6 
smin RI 93% 96% 
2b 41% 195 94% >xi 100% >30 
Endofinfusion 57% 87% 95% 
BT=bkodiag~(medianMcedingtiwatZbforpeticnureceivingheparia=llmio);%lnhib=percent 
inhibition of ex vim piatekt aggregation to 5 pmoLliter a&mine diphphate. See Methods for desdpion of dose 
paoek 
exceeded 30 min for panels II and III (p = 0.003 and 0.001, 
respectively, vs. placebo for bleeding time extension, Fig. 1B). 
Inhibition of platelet aggregation resolved rapidly after cessa- 
tion of tirofiban, and median values at 0.5,15,4 and 8 h after 
infusion are shown for all panels in Figure 2 When vascular 
access sheaths were removed 4 h after cessation of tbe study 
Figure 1. Box and whisker plots. A, Percent inhibition of ex vivo 
platelet aggregation in respome to 5 mter a&no& dimhate 
atSmin,2haodendoftheinfusiwfor~doseregimen.Data 
depicted are median (&se pwl symbols), mean (Mxeatal tbaes), 
25t475th,I~and90thpercentiles~=dosepanelI;~= 
dosepanelu;bixu@es=dosepanel1II.B,Fddincz+se inbleding 
time at 2 h for escalating dose regimens of tirofiban and placebo. Data 
depicted are ohdan (trimgks), mean (dashed lines), 251h 75th, 10th 
and 90th percentiles 
A . 
t 
P . 
drug infusion, the percent inhibition of aggregation was ~50% 
for all peels. 
Advem?cIinkd- There were no deaths, myocar- 
dial infarctions or emergency coronary bypass operations in 
this trial. The incidence of urgent recatheterization or repeat 
coronary angioplasty. or both, is shown in Table 3. ‘The need 
for revascutarization was very low both during study drug 
infusion and before hospital discharge. Although repeat revas- 
cularization appeared to be less frequent during study drug 
infusion (27% in patients treated with tirofiban vs. 5.0% in 
those given placebo) the incidence was so infrequent (less than 
one patient in each panel) that no formal statistical compari- 
son was made. 
HeprorrBpge. nere were no corrective vascular operations 
or intracranial or retroperitoneal hemonhages in this trial. 
One patient in tirofiban panel III received 1 U of packed red 
blood cell transfusion and one patient in the placebo group 
received 2 U of packed red blood cell transfusion. The majority 
of “events” comprised discontinuation of study drug secondary 
to the occurrence of vascular access site hematoma or exces- 
sive oozing lo allow sheath removal and hemostasis. ‘The 
overall incidence of bleeding events was 4.8%, 3.3%, 13.6% 
and 5.0% in treatment panels I, II and III and the placebo 
group, respectively. Study drug was discontinued in one patient 
in panel III with gingival bleeding who manifested a sign&ant 
FIgwe 2. Spontaneous resolution of median percent inhibition oi ex 
vivu platelet aggregation in response lo 5 rmdfliter adeoosine diphas- 
phate is shown over time for each dose regimen (pan& I, II and III). 
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Tab& 3. Recatheterization and Repeat Revawhrization During Study Infusion and at Hospital Discharge 
lnfisiio Period At HoqitalDischqe 
Unable lo Perform Repeat Cardiac Repcat Repeal Cardiac 
GmP NO. woPw Cathelerization 4lww No. Catheterization 
rkaepaell - 21 I (4.R) 0 (l’) I (4.8) 21 I (4.8) I (4.8) 
Dme panel II 30 l(3.3) 0 (0) 0 (0) 30 l(3.3) l(33) 
mle panel III 22 0 (0) IJ (0) I (4.9 22 0 (0) l(45) 
Pooled beparin 20 I (5.0) 0 (0) I (5.0) 20 O(O) l(5.0) 
Pookdtirohban 13 2 (2.7) 0 (0) 2 (27) 73 2 (2.7) 3 (4.1) 
Data are presected as number (sb) of pabents See Method= for derript;oo of pups. 
decrease in hematocrit that was later determined to be spuri- 
ous in origin. One patient who mamfested thrombocytopenia 
with a count of 70,000/mm3 during study drug infusion had 
spontaneous recovery of the platelet count to 93,0Wnm3 after 
intravenous heparin was discontinued, despite the continued 
infusion of tirofibau for 12 additional h. 
Discussion 
Pku.maadpmIcs. ‘Ilk double-blind random&l, placebo- 
controlled dose-r.mging study is ,he first to evaluate the novel 
nonpeptide platelet GP IIb/IIIa receptor antagonist tirofiban 
as a prophylactic adjunct to coronary angioplasty in a high risk 
subset of patients. In this trial, tirofiban demonstrated a 
dose-dependent Inhibition of ex vivo platelet aggregation in 
rcvnse to 5 pmol/liter ADP that was very rapid in onset and 
was susta~! by r continuous intravtnous infusion of the drug. 
fnhibition of platelet aggregation at 5 min after a lO-CLgflrp 
Mua dose of tirofiban exceeded 90%. Previous studies in both 
aimal models and humans have suggested that suppression of 
ADP-induced platelet aggregation to ~20% of baseline is a 
suitable target for pharmacologic efficacy of GP IIb/IIIa recep 
ICI a?. Igonists. This level of antiaggregatory activity has been 
shown tw prevent p!atelet thrombosis in animal models of 
severe &ionary stenosis (13,14,22,23) and to reduce ischemic 
adverse outcomes after high risk coronary angioplasty in 
humans (12,24). Be&use a high level of inhibition (>9O%) was 
seen at the dosing regimen utilized in panel 11 (10 pg/kg and 
0.10 &kg per min infusion), the highest dose regimen was not 
associated with greater platelet antiaggregatory activity, 
though there did appear to be more consistent inhibition 
across the population studied (see Fig. 1A). However, the 
occurrence of hemorrhagic events was increased in patients 
receiving this high dose, suggesting that, with relatively con- 
stant (albeit high) heparin dosing, high levels of inhibition with 
a GP IIb/IlIa blocker could contribute to an increase in such 
events. Although bleeding times were elevated in both of the 
higher dose panels (>30 mir. at 2 h), it is possible that the use 
of a higher concentration of ADP or a more potent agonist, 
such as thrombin receptor-activating peptide, might have 
allowed further separation of tbe antiaggregatory effects of 
these doses. If this were the case. it might help to explain the 
Mettnces in the hemorrhagic event rates between the panels 
II and 111. 
The rapid cessation of platelet inhibition after &amtinu- 
ation of tirofiban is consistent with its relatively short half-life 
of 1.7 h (17,18). Thr percent inhibiiion of platelet aggregation 
was <50?6 fcr all dose panels of tirofiban 4 h after drug 
discontinuation. ‘I’M short half-lie due to reversible binding 
of the GP IIb/lIIa receptor may have important safety impli- 
cations, particularly in patients who require emergency corn 
nary bypass surgery or who have bleeding at the femoral access 
site after coronary angioplasty. Recovery in platelet funaioo 
adequate to allow vasculti and wound bemo&-& can be 
expected to occur within 4 h of cessation of tiroliban. 
Adverse events. Treatment with tirofiban appears to be 
well tolerated. The increase in hemorrhagic events seen at the 
highest dose studied (panel III) was largely related to hemor- 
rhage at the vascular access ite. Only one patient (1.4%) who 
received tirofiban in this study required red cell tra&us& 
This low incidence of hemorrhage was observed despite the 
lack of rigorous weight adjustment in heparin dosii Bleeding 
complications during IIb/IIIa receptor blockade therapy have 
been correlated with both maximal in-laboratory activated 
clotting time and total relative heparin dose (253). Recent 
data (25-27) have suggested that the need for blood transfL 
sion in patients receiving the GP lIb/lIIa receptor blocking 
agent c7E3 may be reduced by limiting the initial heparin bolus 
to 70 U/kg without subsequent adjustment based on acti- 
vated clotting time measurement. As the pre;ent study uti- 
lized a relatively high dose regimen of intravenous beparin 
with weight adjustment to 150 U/kg for the initial bol rs only 
in patients weighing ~75 kg, more stringent weight adjustment 
of heparin dosing might have further reduced the incidence of 
hemorrhage in this trial. Preliminary data from a pilot trial 
of c7W therapy during coronary angioplasty (26) suggest that 
a strategy of rigorous weight adjustment oi heparin (W to 
1CKWkg bolus) and early vascular access sheath removal 
(after cessa!ion of heparin) may substantially reduce bleeding 
complications and the need for blood transfusii. 
The incidence of adverse ischemic clinical outcomes in this 
trial was low. No patient required emergency bypass surgery or 
sustained a myocardial infarction. The need for urgent revas- 
cularizatiorl was low, occufcin8 in one patient or none in each 
panel stud;ed. Formal statistical analyses were not applied to 
these 0utaHne data because of the small sample size. These 
results compare favorably with the expected 10% to 20% rate 
of ischemic complications previously observed in patients with 
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high risk profiles (17333). One potential explanation for this 
relatively low observed event rate may bc the inclusion criteria 
used to define patient risk. Recent observations (29) suggest 
that complex coronary lesion mcrphobgy alone may be a less 
pcwerfd pre%tor of benefkial outcome after coronary an* 
phsty in patients treated with GP Ifb/UIa receptor blockade 
than is the clinical presentation of unstable angina. This 
cbservation is am&tent with the more dramatic reducthn in 
adverse ischemic outames after angioplasty observed in pa- 
tientswbopresentwithachicalsyndmmeofunstableangina 
than in those who present stable angina (30). Because almost 
haIf cf patients in tbe present sh@ were enrolled cn the basii 
of criteria of ~rmplex coron3ry lesion morphology alone 
(Tabk1).omgroupmighthaveanoverallk3serdcgreeof 
benefit from GP IIb/Ua receptor !hckade after coronary 
W+WW- 
CesdPslosa Aitbough determiaation of tbe overall effi- 
caq of tirofiban in reduciug early and late ischemk complica- 
tions tier angioplasty must await a larger scale trial, this study 
is the first to establish a rational and saJe dosing regimen for 
this agent. After a bolus dose of 10 p,jlJ(g and a continuous 
infusioncf0.!0clglkglmin,tircfibanresldtsinrapidand 
profoud inhiiition of platelet aggregation and a low risk of 
asscciated hemorrhage or need for blood transfusion. The 
extremely low incidence of ischemic outcomes (death, myocar- 
dial infarction, repeat -tion) cbselved ill this trial 
precludes any meaningful evaluation of the potential clinical 
benefit attriieble to tiro6ban. A large randomized trial of 
chical efkacy Ah weight adjustment of cooaxnitant heparin 
dosing is underway. 
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